Welcome to our dedicated page for Cardlytics SEC filings (Ticker: CDLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evaluating Cardlytics’ blend of purchase-based advertising, bank-rewards economics, and Bridg subscription revenue means navigating dense SEC language. Reports often run over 200 pages and scatter critical metrics—active financial-institution users, cost-per-served-impression, and segment margins—across exhibits. If you have searched “Cardlytics quarterly earnings report 10-Q filing” or wondered how to track “Cardlytics insider trading Form 4 transactions,” this page eliminates the chase.
Stock Titan’s AI-powered analysis delivers answers the instant a document posts to EDGAR. For investors looking for “Cardlytics SEC filings explained simply,” our engine creates plain-English summaries, redlines new risk factors, and auto-builds valuation tables, so understanding Cardlytics SEC documents with AI takes minutes, not hours. Real-time alerts flag “Cardlytics Form 4 insider transactions real-time,” while side-by-side comparisons present a “Cardlytics annual report 10-K simplified” without diluting nuance.
Practical workflows matter: monitor “Cardlytics executive stock transactions Form 4” before earnings, compare loyalty-program economics via the latest “Cardlytics earnings report filing analysis,” or review governance details inside the “Cardlytics proxy statement executive compensation” section. Need to confirm a sudden partnership? Find the “Cardlytics 8-K material events explained” entry in seconds. With complete coverage of every form type, AI-driven summaries, and timely notifications, you gain the clarity required to act on CDLX disclosures while others are still downloading PDFs.
Cardlytics (CDLX) reported Q3 2025 results showing lower revenue and a large non-cash impairment. Revenue was $52.0 million versus $67.1 million a year ago, reflecting weaker served-based activity while engagement-based revenue grew.
The company recorded $58.8 million of impairment on goodwill and intangible assets, driving an operating loss of $68.9 million and a net loss of $72.7 million for the quarter. Cash and cash equivalents were $43.9 million as of September 30, 2025, with net cash used in operating activities of $3.7 million year-to-date.
On capital structure, Cardlytics fully repaid the remaining $46.1 million of its 2020 convertible notes and had $168.6 million net carrying amount of 4.25% convertible notes due 2029. It also had $46.1 million outstanding on its revolving line of credit. Stockholders’ equity moved to a deficit of $4.7 million, largely due to the impairment. The company recognized a $2.8 million employee retention credit benefit in operating expenses and implemented cost-saving measures, with additional one-time charges expected after quarter-end.
Cardlytics, Inc. (CDLX) reported that it furnished a press release announcing financial results for the three and nine months ended September 30, 2025, and provided details for a conference call to discuss these results and recent corporate highlights. The press release is included as Exhibit 99.1.
The information under Item 2.02 (Results of Operations and Financial Condition) and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. The company listed exhibits under Item 9.01, including the press release and the Inline XBRL cover page.
Cardlytics (CDLX) reported an insider equity change by a director. On October 30, 2025, 6,148 restricted stock units converted into 6,148 shares of common stock, shown with transaction code M (conversion of a derivative security) at a stated price of $0, consistent with RSU settlement.
The RSUs were granted on October 30, 2024 and vested in full one year later. After the settlement, the reporting person holds 6,148 shares with direct ownership. No sales were reported in this filing.
Nick Lynton, Chief Legal & Privacy Officer of Cardlytics, Inc. (CDLX), reported multiple vesting and a sale related to restricted stock units. On 10/01/2025 the reporting person had 10,630, 581 and 1,578 RSUs treated as acquired (each converts into one share) and those awards increased their reported beneficial ownership to 122,425 shares before a sale. On 10/02/2025 the reporting person sold 6,098 shares at a weighted average price of $2.271 (individual sale prices ranged $2.21–$2.36) and the filing shows 116,327 shares owned after the sale. The filing states the sale was made solely to satisfy tax withholding from RSU vesting and discloses original grant sizes and vesting schedules for each RSU award.
Amit Gupta, Cardlytics, Inc. (CDLX) Chief Executive Officer and director, reported vesting and sales tied to restricted stock units. On 10/01/2025 14,350 RSUs vested (each convertible into one share) and were recorded as an acquisition event. To cover tax withholding for that vesting, 7,799 shares were sold on 10/02/2025 at a weighted average price of $2.271, with reported sale prices ranging from $2.21 to $2.36. After these transactions, the Reporting Person beneficially owned 498,310 shares directly and had 28,699 RSU-based shares remaining that will convert to common stock if vesting conditions are met. The original RSU grant totaled 114,796 shares and vests in eight equal installments through 04/01/2026.
Cardlytics, Inc. (CDLX) Form 144 notice shows an insider intends to sell 8,493 shares of common stock, with an aggregate market value of $19,286.75, on or about 10/02/2025 through Fidelity Brokerage Services LLC on NASDAQ. The shares were acquired on 10/01/2025 by restricted stock vesting as compensation. The filer also reported two prior sales in the past three months: 7,324 shares sold on 07/02/2025 for $13,055.76 and 26,048 shares sold on 08/15/2025 for $31,695.21. The filer certifies no undisclosed material adverse information is known.
Cardlytics, Inc. (CDLX) disclosure shows a proposed insider sale of 7,799 common shares through Fidelity Brokerage Services on 10/02/2025 with an aggregate market value of $17,710.75. The shares were acquired on 10/01/2025 upon restricted stock vesting and were granted as compensation. The filing lists total common shares outstanding as 53,236,901. The filer also reported three sales by Amit Gupta in the prior three months: 6,725 shares on 07/02/2025 (gross proceeds $11,987.99), 68,260 shares on 08/18/2025 (gross proceeds $76,806.15), and 68,685 shares on 08/19/2025 (gross proceeds $76,803.57), totaling 143,670 shares and $165,597.71 in gross proceeds. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Cardlytics, Inc. (CDLX) filed a Form 144 reporting a proposed sale of 6,098 common shares acquired on 10/01/2025 via restricted stock vesting. The filing lists an aggregate market value of $13,847.95 and an approximate sale date of 10/02/2025 on NASDAQ. The filer previously sold 5,271 shares on 07/02/2025 for $9,396.09. The form includes the standard representation that the seller does not possess undisclosed material information about the issuer.
CAS Investment Partners, Sosin Master and related entities report combined shared beneficial ownership of 5,198,067 shares of Cardlytics (CDLX), representing approximately 9.8% of the outstanding common stock based on 53,236,901 shares outstanding as of July 31, 2025. Sosin Master directly holds 3,198,584 shares (about 6.0%) and CSWR directly holds 1,999,483 shares (about 3.8%). The filing states the Sosin entities purchased shares in open market transactions funded primarily with working capital; aggregate purchase prices were approximately $88.6 million for Sosin Master and $65.0 million for CSWR. Reporting persons disclose shared voting and dispositive power only and note holdings of convertible notes with principal amounts of $13.74 million (Sosin Master) and $7.50 million (CSWR), which may be settled in cash or shares at the issuer’s option.
FAQ
What is the current stock price of Cardlytics (CDLX)?
What is the market cap of Cardlytics (CDLX)?
